---
title: "Cardiovascular News – Issue 74 – September 2024: US Edition"
date: "2024-08-22T09:21:17.000Z"
publishedDate: "22 août 2024"
summary: "In this issue: Is it time for rethinking major adverse cardiovascular events (MACE) as an endpoint in cardiovascular clinical trials? Yes, say trialists."
importance: ""
sourceUrl: "https://cardiovascularnews.com/cardiovascular-news-issue-74-september-2024-us-edition/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2024-08-22-cardiovascular-news-issue-74-september-2024-us-edition"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2024/08/CVN-US-cover_edited.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/cardiovascular-news-issue-74-september-2024-us-edition/"
---

![Cardiovascular News – Issue 74 – September 2024: US Edition](https://cardiovascularnews.com/wp-content/uploads/sites/14/2024/08/CVN-US-cover_edited.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/cardiovascular-news-issue-74-september-2024-us-edition/*

## L’essentiel

In this issue: Is it time for rethinking major adverse cardiovascular events (MACE) as an endpoint in cardiovascular clinical trials? Yes, say trialists.

## Lien source

https://cardiovascularnews.com/cardiovascular-news-issue-74-september-2024-us-edition/
